Table 1 Fast facts about flibanserin Brand name: Addyi Indication:
Hypoactive sexual desire disorder Approval date: August 2015 Availability date: October 2015 Manufacturer: Sprout Pharmaceuticals Dosing forms: 100 mg tablets Recommended dosage: 100 mg at bedtime Table 2 Results of clinical trials evaluating efficacy of flibanserin Study 1 Study 2 Flibanserin Placebo Flibanserin Placebo (n = 280) (n = 290) (n = 365) (n = 372) Number of satisfying sexual events (per 28 days) Baseline (mean) 3.
The report provides a snapshot of the global therapeutic landscape of Female
Hypoactive Sexual Desire DisorderCaption: The panel voted 18-6 in favor of flibanserin for
hypoactive sexual desire disorder.
They were individually assessed by clinical interview, and met the DSM-IV diagnostic criteria for
hypoactive sexual desire disorder (American Psychiatric Association, 1994).
Biopharmaceutical company AMAG Pharmaceuticals (NasdaqGS:AMAG) and Palatin Technologies (NYSE MKT:PTN) Monday launched an agreement for exclusive North American rights to develop and commercialise Rekynda for on-demand treatment of
hypoactive sexual desire disorder (HSDD) in pre-menopausal women.
Bupropion sustained release for the treatment of
hypoactive sexual desire disorder in premenopausal women.
At a joint meeting of two Food and Drug Administration advisory panels in June, members of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 18-6 that the overall benefit-risk profile of flibanserin supported approval for treating
hypoactive sexual desire disorder (HSDD) in premenopausal women, provided that certain risk management options beyond labeling were implemented.
ClickPress, Mon Mar 09 2015] Global Markets Direct's, 'Female
Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2015', provides an overview of the Female
Hypoactive Sexual Desire Disorder's therapeutic pipeline.
The study, which was presented at the annual conference of the American Society for Reproductive Medicine in Denver, Colorado, involved 19 women diagnosed with
hypoactive sexual desire disorder and seven women with normal sexual drive.
1,2) Among these is
hypoactive sexual desire disorder (HSDD), a condition that causes marked distress and interpersonal difficulties.
The first step in treating
hypoactive sexual desire disorder is to identify causes that can be treated.
ABSTRACT: This study addressed two issues concerning the clinical and theoretical relevance of depression to
hypoactive sexual desire disorder (HSD): (a) whether reliable differences among depressed, mildly depressed, and non-depressed women with HSD could be identified; and (b) whether depression influenced participation in or outcome following orgasm consistency training (OCT).
